terconazole vaginal

Action and Spectrum

Actions and Spectrum: 

Actions: 

Terconazole is a drug that fights fungus. By breaking down the fungal cell membrane, it eliminates the infection on your skin and prevents it from growing. 

Spectrum: 

Regarding terconazole vaginal, its range of action is limited to its antifungal properties against specific species of Candida, especially those that cause vaginal yeast infections, or vulvovaginal candidiasis. 

Drug Interaction

Adverse Reaction

Frequency defined 

>10% 

Headache  

1-10% 

Dysmenorrhea 

Abdominal pain 

Fever 

Chills 

Vulvar/vaginal burning  

<1% 

Flu-like syndrome 

Polyuria 

Vulvar itching, edema, soreness or discharge 

Itching or burning of reproductive organs of partner 

Black Box Warning

Black Box Warning: 

It’s just you and this medication. Don’t give this medication to anyone else. Make sure kids cannot access any medications. Inform your physician or pharmacist before using this medication if you have any allergies, including to other azole antifungal drugs like fluconazole or clotrimazole. Inactive chemicals in this product have the potential to trigger allergic reactions or other issues. For further information, consult your pharmacist. 

Contraindication / Caution

Contraindication/Caution: 

Contraindications 

• Hypersensitivity 
• Allergic to ciclesonide 

Cautions 

• Fever 
• Chills 
• Sensitization 
• Flu-like symptoms 
• Irritation 
• No concurrent use with vaginal contraceptive diaphragms 

Pregnancy / Lactation

Pregnancy consideration:  

No data is available regarding the administration of the drug during pregnancy. 

Breastfeeding warnings:  

No data is available regarding the excretion of drug in breast milk. 

Pregnancy category: C 

Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester. 

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. 

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    

Category N: No data is available for the drug under this category. 

Pharmacology

Pharmacology: 

Unknown; could change the permeability of fungal cell membranes 

Pharmacodynamics: 

One triazole antifungal medication that can be injected intravaginally is terconazole. Despite the fact that terconazole and other triazoles have three nitrogens in the azole ring, it shares structural similarities with imidazole-derived antifungal medicines. Terconazole prevents the formation of ergosterol by blocking the 14-alpha-demethylase (lanosterol 14-alpha-demethylase).

The structure and numerous activities of the fungal membrane are disrupted when ergosterol levels in the membrane are low, which inhibits fungal growth. It’s possible that terconazole works against fungi by obstructing the permeability of fungal cell membranes.

In susceptible fungi, cytochrome P450 14-alpha-demethylase is inhibited by terconazole and other triazole antifungal drugs. This results in the accumulation of lanosterol and other methylated sterols and a reduction in the concentration of ergosterol. The structure and function of the fungal cell are disrupted when ergosterol in the membrane is depleted, which lowers or inhibits fungal growth. 

Pharmacokinetics: 

Absorption 

In humans, absorption varied between 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized patients with tubal ligations after intravaginal terconazole injection. 

Distribution 

Protein bound: 94.9% 

Metabolism 

Drugs that are absorbed systemically seem to be digested quickly and thoroughly. The main oxidative processes that terconazole goes through include conjugation, dioxolane ring cleavage, and N- and O-dealkylation. 

Elimination and Excretion 

The half-life is 6.9 hours 

The elimination of radioactivity occurred through both the renal (32–56%) and fecal (47–52%) pathways after oral (30 mg) administration of 14C-labelled terconazole. 

Adminstartion

Administration: 

Follow the directions on the label exactly, or as your physician has prescribed. Never use more, less, or any duration of time than is advised. Terconazole vaginal should not be used orally. It should only be used in the vagina. 

Instructions for safe and efficient use of this drug are provided to the patient. Pay close attention to these directions. If you have any questions, speak with your physician or pharmacist. 

Both a cream and a vaginal suppository are forms of terconazole vaginal. An applicator for measuring and inserting the vaginal medication is included with each form. Terconazole cream is also offered in prefilled applicators, each of which has a single daily dosage. If preferred, the vaginal suppository can be inserted with your finger. 

Both before and after applying the cream or suppository, wash your hands. For three to seven days straight, terconazole vaginal is typically given once daily at bedtime. Observe what your doctor has prescribed. 

Take this drug for the entire recommended duration. It’s possible for your symptoms to become better before the infection totally goes away. Missing doses can also make you more susceptible to infections that become resistant to antifungal medications. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: terconazole vaginal 

Pronounced: ter-KON-uh-zole vuh-JY-nuhl 

Why do we use terconazole vaginal? 

Terconazole is an antifungal drug used to treat fungal infections. 

Treatment for vaginal Candida (yeast) infections, such as vulvovaginal candidiasis (moniliasis), involves the use of terconazole vaginal (for vaginal use).